MedTrace Logo

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

NCT00591149 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-06-14

Study results available
· View outcomes & findings →

Summary

A study of Oxaliplatin and Docetaxel followed by Cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size

Conditions

Interventions

DRUG

Oxaliplatin

130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles

DRUG

Docetaxel

60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles

DRUG

Cetuximab

400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Chao Huang, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591149 on ClinicalTrials.gov